Abstract
Disease states involving both, cardial and renal function have been defined as separate
entity called cardiorenal (reno-cardial) syndromes type 1 – 5. Due to the underlying
disease this syndrome is increasingly common amongst the ageing population on the
western world and makes physicians facing complex interactions of cardiological and
nephrological therapy. Therapeutic approaches include the careful assessment of cardiovascular
risk factors and the optimized therapy of both, cardiac and renal disease using so
far evaluated strategies such as RAS-blockade, diuretic therapy and in distinct stages
also extracorporeal fluid removal by ultrafiltration in the acute and peritoneal dialysis
in the chronically unstable patient.
Kernaussagen
-
Die gegenseitige Beeinflussung von Herz- und Nierenerkrankungen spiegelt sich in der
Definition des kardiorenalen Syndroms (KRS) wider (Tab. [1]). Das KRS ist im klinischen Alltag häufig und bedarf einer interdisziplinären Therapie.
-
Die akute Nierenschädigung wird derzeit anhand des Verlaufs von Serumkreatinin und
Urinausscheidung in die RIFLE-Stadien eingeteilt (Tab. [2]). Grundlage für die Definition einer chronischen Nierenschädigung bzw. Funktionseinschränkung
ist entweder der Nachweis einer reduzierten geschätzten glomerulären Filtrationsrate
(„estimated GFR”) über mehr als 3 Monate oder aber der Nachweis renaler Schäden bei
normaler eGFR (z. B. Proteinurie oder nephritisches Sediment).
-
Beim KRS werden 5 Typen unterschieden: Bei den Typen 1 und 2 führt eine akute (Typ
1) oder chronische (Typ 2) Herzerkrankung zur Verschlechterung der Nierenfunktion,
bei den Typen 3 und 4 führt eine akute (Typ 3) oder chronische (Typ 4) Nierenfunktionseinschränkung
zur Störung der kardialen Funktion und beim Typ 5 sind es systemische Krankheitsbilder,
die zur kardialen und renalen Funktionsstörung führen. Bei den chronischen Formen
(Typ 2 und 4) ist es dabei oft schwierig zu unterscheiden, ob die Herz- oder die Nierenerkrankung
das primäre Problem waren.
-
Therapeutisch gelten beim KRS die Regeln der Behandlung kardialer bzw. renaler Krankheitsbilder.
Dabei sind die Diuretikatherapie und die RAAS-Blockade die wichtigsten Therapieoptionen.
Eine akut eingeschränkte myokardiale Funktion muss vorrangig behandelt werden – im
Zweifelsfall auch ohne Rücksicht auf die Nierenfunktion.
Literatur
- 1
Van Biesen W, Vanholder R, Lameire N.
Defining acute renal failure: RIFLE and beyond.
Clin J Am Soc Nephrol.
2006;
1
1314-1319
- 2
Jose P, Skali H, Anavekar N et al.
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction
after myocardial infarction.
J Am Soc Nephrol.
2006;
17
2886-2891
- 3
Forman D E, Butler J, Wang Y et al.
Incidence, predictors at admission, and impact of worsening renal function among patients
hospitalized with heart failure.
J Am Coll Cardiol.
2004;
43
61-67
- 4
Heywood J T, Fonarow G C, Costanzo M R et al.
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients
hospitalized with acute decompensated heart failure: a report from the ADHERE database.
J Card Fail.
2007;
13
422-430
- 5
Elsayed E F, Tighiouart H, Griffith J et al.
Cardiovascular disease and subsequent kidney disease.
Arch Intern Med.
2007;
167
1130-1136
- 6
Abuelo J G.
Normotensive ischemic acute renal failure.
N Engl J Med.
2007;
357
797-805
- 7
Rihal C S, Textor S C, Grill D E et al.
Incidence and prognostic importance of acute renal failure after percutaneous coronary
intervention.
Circulation.
2002;
105
2259-2264
- 8
Gruberg L, Mintz G S, Mehran R et al.
The prognostic implications of further renal function deterioration within 48 h of
interventional coronary procedures in patients with pre-existent chronic renal insufficiency.
J Am Coll Cardiol.
2000;
36
1542-1548
- 9
McCullough P A, Wolyn R, Rocher L L et al.
Acute renal failure after coronary intervention: incidence, risk factors, and relationship
to mortality.
Am J Med.
1997;
103
368-375
- 10
Anavekar N S, McMurray J J, Velazquez E J et al.
Relation between renal dysfunction and cardiovaskular outcomes after myocardial infarction.
N Engl J Med.
2004;
351
1285-1295
- 11
Foley R N, Parfrey P S, Sarnak M J.
Clinical epidemiology of cardiovascular disease in chronic renal disease.
Am J Kidney Dis.
1998;
32
112-119
- 12
Bagshaw S M, Cruz D N, Aspromonte N et al.
Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus
Conference.
Nephrol Dial Transpl.
2010;
25
1406-1416
- 13
Cushman W C, Evans G W, Byington R P et al.
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
N Engl J.
Med ;
362
1575-1585
- 14
Appel L J, Wright Jr J T , Greene T et al.
Intensive blood-pressure control in hypertensive chronic kidney disease.
N Engl J.
Med ;
363
918-929
- 15
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) .
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular
filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.
Lancet.
1997;
349
1857-1863
- 16
Peterson J C, Adler S, Burkart J M et al.
Blood pressure control, proteinuria, and the progression of renal disease. The Modification
of Diet in Renal Disease Study.
Ann Intern Med.
1995;
123
754-762
- 17
Lewis E J, Hunsicker L G, Bain R P et al.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The
Collaborative Study Group.
N Engl J Med.
1993;
329
1456-1462
- 18
Wapstra F H, Navis G, de Jong P E et al.
Prognostic value of the short-term antiproteinuric response to ACE inhibition for
prediction of GFR decline in patients with nondiabetic renal disease.
Exp Nephrol.
1996;
4 (Suppl. 1)
47-52
- 19
Berger A K, Duval S, Krumholz H M.
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients
with end-stage renal disease and an acute myocardial infarction.
J Am Coll Cardiol.
2003;
42
201-208
- 20
Drueke T B, Locatelli F, Clyne N et al.
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
N Engl J Med.
2006;
355
2071-2084
- 21
Pfeffer M A, Burdmann E A, Chen C Y et al.
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
N Engl J Med.
2009;
361
2019-2032
- 22
Besarab A, Goodkin D A, Nissenson A R.
The normal hematocrit study – follow-up.
N Engl J Med.
2008;
358
433-434
- 23
Gaede P, Vedel P, Parving H H et al.
Intensified multifactorial intervention in patients with type 2 diabetes mellitus
and microalbuminuria: the Steno type 2 randomised study.
Lancet.
1999;
353
617-622
- 24
Mann J F, Schmieder R E, McQueen M et al.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk
(the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet.
2008;
372
547-553
- 25
Parving H H, Persson F, Lewis J B et al.
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
N Engl J Med.
2008;
358
2433-2446
- 26
McMurray J J, Pitt B, Latini R et al.
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic
heart failure.
Circ Heart Fail.
2008;
1
17-24
- 27
Juurlink D N, Mamdani M M, Lee D S et al.
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med.
2004;
351
543-551
- 28
Chua D, Lo A, Lo C.
Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis:
is it safe?.
Clin.
Cardiol;
33
604-608
- 29
Howard P A, Dunn M I.
Aggressive diuresis for severe heart failure in the elderly.
Chest.
2001;
119
807-810
- 30
Wilcox C S.
New insights into diuretic use in patients with chronic renal disease.
J Am Soc Nephrol.
2002;
13
798-805
- 31
Costanzo M R, Guglin M E, Saltzberg M T et al.
Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated
heart failure.
J Am Coll Cardiol.
2007;
49
675-683
- 32
Sanchez J E, Ortega T, Rodriguez C et al.
Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart
failure.
Nephrol Dial.
Transplant ;
25
605-610
- 33
Khalifeh N, Vychytil A, Horl W H.
The role of peritoneal dialysis in the management of treatment-resistant congestive
heart failure: A European perspective.
Kidney Int Suppl.
2006;
103
S72-75
PD Dr. med. Bernd Hohenstein
Bereich Nephrologie
Medizinische Klinik III
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Fetscherstr. 74
01307 Dresden
Telefon: 0351-458-18639
Fax: 0351-458-5333
eMail: bernd.hohenstein@uniklinikum-dresden.de
